-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Figure: IGF2BP2 overexpression leads to liver steatosis (left), inflammation (middle), and hepatocyte apoptosis (right) in mice
Nonalcoholic steatohepatitis (NASH) is characterized by liver steatosis, inflammation, and damage, and has become one of the leading causes of end-stage liver disease such as hepatocellular carcinoma
More than two decades ago, the "double hit" theory was proposed to explain the pathogenesis of NASH, in which steatosis is the "first hit" and oxidative stress is the "second hit"
Researchers from Zhongshan Hospital of Fudan University and the Sixth People's Hospital Affiliated to Shanghai Jiaotong University and other collaborators have jointly identified a novel molecule in the pathogenesis of NASH through three diet- or compound-induced mouse models of chronic liver inflammation and injury mechanism
In the present study, through unbiased RNA-sequencing analysis and subsequent validation, we identified insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) as a novel N 6 -methyladenosine (m 6 A) modified reader, Significantly increased in NASH mouse liver
In conclusion, this study confirmed that IGF2BP2 is a key regulator in the occurrence and development of NASH
